LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Winner of Qualcomm Tricorder XPrize Unveiled at AACC

By LabMedica International staff writers
Posted on 08 Jun 2017
Image: The DxtER \"tricorder\" health monitor and diagnostic device (Photo courtesy of XPRIZE).
Image: The DxtER \"tricorder\" health monitor and diagnostic device (Photo courtesy of XPRIZE).
A highlight of the July 30 - August 3, 2017, AACC Annual Scientific Meeting & Clinical Lab Expo (San Diego, CA, USA) will be the session dedicated to the unveiling of the winner of the Qualcomm Tricorder XPrize (Culver City, CA, USA) competition.

The 10 million USD global competition, which was announced in 2012, challenged 34 research teams to produce a lightweight device (a "tricorder") that consumers could have at their fingertips to diagnose a health condition or monitor their vital signs without the need to consult a medical professional. To qualify the device had to be capable of diagnosing at least 13 health conditions and continuously monitoring five vital signs, all with a consumer-friendly interface and weighing no more than five pounds (2.27 kilograms).

In the science-fictional Star Trek universe, a tricorder was a multifunction hand-held device used for sensor scanning, data analysis, and recording data. The standard tricorder was a general-purpose device used primarily to scout unfamiliar areas, make detailed examination of living things, and record and review technical data. The medical tricorder was used by doctors to help diagnose diseases and collect bodily information about a patient; the key difference between this and a standard tricorder was a detachable hand-held high-resolution scanner stored in a compartment of the tricorder when not in use.

The winner of the top prize of 2.6 million USD was Final Frontier Medical Devices, a Pennsylvania-based team led by Dr. Basil Harris, an emergency medicine physician, and his brother George Harris, a network engineer, for their artificial intelligence-based engine, DxtER, which learns to diagnose medical conditions by integrating learnings from clinical emergency medicine with data analysis from actual patients.

DxtER was designed to monitor the individual's health and diagnose illnesses away from the hospital or doctor's office setting. DxtER functions autonomously, but can also share important information with healthcare providers. At the heart of DxtER is an artificially intelligent engine that learned to diagnose by integrating years of experience in clinical emergency medicine with data analysis from actual patients having a variety of medical conditions and outcomes. Included with DxtER is an assortment of non-invasive sensors custom-designed to collect data about vital signs, body chemistry, and biological functions. The diagnostic engine synthesizes the health data to make a quick and accurate assessment.

Dynamical Biomarkers Group was awarded the second place in the Qualcomm Tricorder XPRIZE competition for their prototype, which links diagnostic algorithms with analytical methodology in a user-friendly device, all controlled through a smartphone.

Final Frontier Medical Devices team member Philip Charron and Dynamical Biomarkers Group team member Dr. Chung-Kang Peng will describe their revolutionary technologies in a major session at the 69th AACC Annual Scientific Meeting.

Related Links:
AACC Annual Scientific Meeting & Clinical Lab Expo
Qualcomm Tricorder XPrize

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Gold Member
Hematology Analyzer
Medonic M32B

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more